![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune...
Amgen Completes Acquisition Of Otezla® (apremilast) Differentiated Therapy Strengthens Amgen's Long-Standing Expertise in Inflammation PR Newswire THOUSAND OAKS, Calif., Nov. 21, 2019 THOUSAND...
Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to...
Die Kombination aus Lenalidomid (REVLIMID®) und Rituximab (R2) hat das Potenzial, eine chemotherapiefreie Behandlungsoption für rezidivierte oder refraktäre Patienten mit follikulärem Lymphom zu...
Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 PR Newswire NEW YORK, Nov. 19, 2019 NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc...
NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the...
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous...
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing PR Newswire WALTHAM...
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA-approved treatment for...
Nearly 70 abstracts, including more than 20 oral presentations highlight diverse portfolio of innovative treatment modalities, including potentially transformative cell therapies Celgene...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | -5.7 | -15.0197628458 | 37.95 | 37.95 | 32.25 | 125 | 35.67 | CS |
12 | -5.7 | -15.0197628458 | 37.95 | 37.95 | 32.25 | 125 | 35.67 | CS |
26 | -5.7 | -15.0197628458 | 37.95 | 37.95 | 32.25 | 125 | 35.67 | CS |
52 | 6.75 | 26.4705882353 | 25.5 | 37.95 | 25.5 | 934 | 31.29458255 | CS |
156 | 9.5 | 41.7582417582 | 22.75 | 37.95 | 19.32 | 578 | 28.94069047 | CS |
260 | 19.25 | 148.076923077 | 13 | 37.95 | 13 | 503 | 25.41895854 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions